BD Onclarity™ HPV Assay is the only FDA-approved HPV assay to individually identify and report genotypes beyond 16, 18 and 45 FRANKLIN LAKES, N.J., July 22, 2020 /PRNewswire/ -- BD (Becton, Dickinson ...

ATHENA study shows the cobas HPV Test advances the standard of care by providing valuable information on the risks associated with the genotypes which cause 70 percent of cervical cancer Results from ...

Persistent HPV infection is the principal cause of cervical cancer. HPV-based screening is effective but has limited ...

FRANKLIN LAKES, N.J., Nov. 12, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market ...

- Presented a roadmap to enhance screening reliability at the world's leading multidisciplinary HPV congress held in Portugal from March 16-19 - Demonstrated how self-collected samples for HPV testing ...

The American Society for Colposcopy and Cervical Pathology (ASCCP) has issued new guidelines reflecting the importance of extended genotyping in HPV testing to support an enhanced standard of patient ...

Abbott Laboratories is adding HPV screening to its "Alinity m" family of diagnostic assays following U.S. Food & Drug Administration approval. Abbott said in a press release that the FDA approved its ...

Testing for HPV types 16 and 18 in women with minor cervical lesions may be useful as a second triage after high-risk HPV testing to determine which patients should go on to colposcopy. The results of ...

As the science and technology behind genomic sequencing progresses, high-throughput molecular testing has increasingly become a crucial tool in identifying diseases in their earliest stages. Despite ...

In 2020, American Cancer Society released an updated cervical cancer screening guideline calling for primary human papillomavirus (HPV) screening as the preferred strategy. Utility of HPV primary ...